GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Mavacamten - CAMZYOS capsules

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Mavacamten - CAMZYOS capsules

Product / population
Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.
Renal method
Indexed eGFR, mL/min/1.73 m2
Source revision
4/2025
Retrieved
2026-09-10
Local review status
Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Before use: Mavacamten - CAMZYOS capsules

PK observations are not a renal dosing ladder; the source groups overlap at 30.

What to reconcile: Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

Mavacamten - CAMZYOS capsules

Open original reference

DailyMed / NLM exact product labeling · Adult symptomatic obstructive hypertrophic cardiomyopathy. Renal pharmacokinetics only.

Renal method: Indexed eGFR, mL/min/1.73 m2
Source date: 4/2025
Retrieved: 2026-09-10

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding

Review current full CAMZYOS monitoring and interaction requirements; do not select a dose from these PK rows.

Dialysis evidence: No dialysis regimen established in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

CAMZYOS - renal pharmacokinetic evidence
eGFR, mL/min/1.73 m2Source-specific dose / instruction
60-89 and 30-59No clinically important PK differences observed
15-30Effect unknown
<15 including dialysisEffect unknown
Read the retained text before reformatting

CAMZYOS - renal pharmacokinetic evidence

eGFR, mL/min/1.73 m2Source-specific dose / instruction
60-89 and 30-59No clinically important PK differences observed
15-30Effect unknown
<15 including dialysisEffect unknown

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

RDM63-official-mavacamten-d7c18e961d-C1 · Source locator: Clinical pharmacology 12.3; boxed warning and dosing safeguards

Source-specific limits

The printed groups overlap at exactly 30; no boundary is corrected or dose inferred.

Heart-failure precautions, echocardiographic LVEF monitoring and CYP-related interaction rules govern use. Do not initiate when LVEF is below 55%; interrupt below 50% per the selected label.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b
Retrieved
2026-09-10
Exact label title
Mavacamten - CAMZYOS capsules
DailyMed Set ID
669c936b-3ee6-4e36-8a22-79dd11b1255b
Label revision
4/2025
Renal-function method
Indexed eGFR, mL/min/1.73 m2
Source date/version
4/2025
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
3c0ec8c8d128c346cbbb100c64cd082025e7d405379c3819ce88a4105cbe6fec

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=mavacamten&s1=RDM63-official-mavacamten-d7c18e961d&h1=c3145c87d55531347e34cc463ca20fa7cccd7e8a220967052b8eaf76e3703e19